InMed Pharmaceuticals Form 3 shows director with no holdings

Rhea-AI Filing Summary

InMed Pharmaceuticals (INM) disclosed an initial beneficial ownership filing. A director submitted a Form 3 indicating their status as a Director and reporting no securities beneficially owned as of the event date 10/09/2024.

The Form 3 was filed by one reporting person and lists no direct or indirect holdings in either non-derivative or derivative securities. The filing is signed "/s/ Neil Klompas" and dated 10/17/2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Accepted by SEC EDGAR 10/17/2025 - 08:33 PM Learn about SEC filing dates

FAQ

What did InMed Pharmaceuticals (INM) file?

A Form 3 initial statement of beneficial ownership by a director.

What is reported about the director’s holdings in INM?

No securities are beneficially owned by the reporting person as stated in the filing.

What is the event date for this Form 3?

The event date is 10/09/2024.

How many reporting persons are included?

The Form 3 was filed by one reporting person.

Were any derivative securities disclosed?

No. The filing lists no derivative securities beneficially owned.

Who signed the filing and when?

The filing was signed by Neil Klompas on 10/17/2025.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Klompas Neil A

(Last) (First) (Middle)

C/O INMED PHARMACEUTICALS INC.

1445-885 WEST GEORGIA ST.

(Street)

VANCOUVER A1 V6C3E8

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
10/09/2024

3. Issuer Name and Ticker or Trading Symbol
InMed Pharmaceuticals Inc. [ INM ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Neil Klompas	10/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.